|

Medium dose for 15-HPV vaccine Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • Shanghai Bovax Biotechnology Co., Ltd.1

Indications

  • Genital Wart1
  • HPV-Related Intraepithelial Neoplasia1
  • HPV Infection1
  • HPV-Related Carcinoma1
  • Cancer1

Other1 trial

To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.